Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Grifols ADR Representing One Non-Voting Ord Shs Class B GRFS

Healthcare Biotechnology
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale... see more

Recent & Breaking News (NDAQ:GRFS)

The Schall Law Firm Begins Probe Into Claims Against Grifols SA And Urges Affected Investors To Make Contact

Accesswire June 23, 2024

The Schall Law Firm Initiates Investigation Into Allegations Against Grifols SA And Encourages Impacted Investors To Reach Out

Accesswire June 22, 2024

The Schall Law Firm Begins Probe Into Claims Against Grifols SA And Urges Affected Investors To Make Contact

Accesswire June 21, 2024

The Schall Law Firm Initiates Investigation Into Allegations Against Grifols SA And Encourages Impacted Investors To Reach Out

Accesswire June 20, 2024

Claims Against Grifols SA The Schall Law Firm Begins Probe And Urges Affected Investors To Make Contact

Accesswire June 19, 2024

Allegations Against Grifols SA The Schall Law Firm Initiates Investigation And Encourages Impacted Investors To Reach Out

Accesswire June 18, 2024

Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group

GlobeNewswire June 18, 2024

Claims Against Grifols Sa Schall Law Firm Begins Probe And Urges Affected Investors To Make Contact

Accesswire June 17, 2024

Grifols' Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies

GlobeNewswire June 17, 2024

Allegations Against Grifols, S.A.: Schall Law Firm Initiates Investigation And Encourages Impacted Investors To Reach Out

Accesswire June 11, 2024

Charges Against Grifols, S.A.: Schall Law Firm Launches Examination And Calls On Affected Investors To Participate

Accesswire June 9, 2024

Accusations Against Grifols, S.A.: Schall Law Firm Initiates Inquiry And Invites Impacted Investors To Engage

Accesswire June 8, 2024

Claims Against Grifols, S.A.: Schall Law Firm Begins Probe And Calls On Affected Investors To Connect

Accesswire June 7, 2024

Allegations Against Grifols, S.A.: Schall Law Firm Initiates Investigation And Encourages Impacted Investors To Reach Out

Accesswire June 6, 2024

Grifols, S.A. Allegations: Schall Law Firm Commences Probe and Invites Affected Investors to Connect

Accesswire June 5, 2024

The Schall Law Firm is commencing a probe into allegations against Grifols, S.A. and invites investors who have suffered losses to get in touch

Accesswire June 4, 2024

GRFS IMPORTANT ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm

Accesswire June 3, 2024

INVESTIGATION PROGRESS UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm

Accesswire June 2, 2024

INVESTIGATION PROGRESS REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm

Accesswire June 1, 2024

INVESTIGATION PROGRESS ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm

Accesswire May 31, 2024